首页> 外文期刊>Biopharmaceutics and Drug Disposition >Pharmacokinetic variability of flecainide in younger Japanese patients and mechanisms for renal excretion and intestinal absorption
【24h】

Pharmacokinetic variability of flecainide in younger Japanese patients and mechanisms for renal excretion and intestinal absorption

机译:氟卡尼特在日本年轻患者中的药代动力学变异及肾脏排泄和肠道吸收的机制

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The aims of the present study were to evaluate the variability of pharmacokinetics of flecainide in young Japanese patients and to investigate the mechanisms of renal excretion and intestinal absorption of the drug using cultured epithelial cells. First the plasma concentration data of flecainide was analysed in 16 Japanese patients aged between 0.07 and 18.30 years using a one-compartment model. Considerable interindividual variability was observed in the oral clearance (CL/F) and the apparent volume of distribution (V/F) of flecainide in the young patients. Flecainide was transported selectively in the basolateral-to-apical direction in P-glycoprotein-expressing renal epithelial LLC-GA5-COL150 cell monolayers. The uptake of flecainide into intestinal epithelial LS180 cells was decreased significantly by acidification of the extracellular medium, and was inhibited by tertiary amines, such as diphenhydramine and quinidine. These findings in the present study suggest that flecainide is excreted by P-glycoprotein in the renal tubule and is taken up by the postulated H~+/ tertiary amine antiporter in the intestine, and that functional variability of not only the hepatic drug-metabolizing enzymes, but also the transporters in the kidney and intestine, may be responsible for the interindividual variability of systemic clearance (CL) and/or the bioavailability (F) of flecainide.
机译:本研究的目的是评估氟卡尼在日本年轻患者中药代动力学的变异性,并利用培养的上皮细胞研究肾脏排泄和肠道吸收药物的机制。首先,采用单室模型分析了16名年龄在0.07至18.30岁之间的日本患者中氟卡尼的血浆浓度数据。在年轻患者中,氟卡尼的口服清除率(CL / F)和表观分布量(V / F)存在明显的个体差异。氟卡尼特在表达P-糖蛋白的肾上皮LLC-GA5-COL150细胞单层中沿基底外侧至顶部方向选择性转运。通过细胞外培养基的酸化,氟卡尼对肠上皮LS180细胞的摄取显着降低,并被叔胺(如苯海拉明和奎尼丁)抑制。本研究中的这些发现表明,氟卡尼可通过肾小管中的P-糖蛋白排泄,并被肠道中假定的H〜+ /叔胺逆向转运蛋白吸收,而且不仅肝药物代谢酶的功能存在变异性,以及肾脏和肠道中的转运蛋白,可能是氟卡尼胺的个体间系统清除率(CL)和/或生物利用度(F)的个体差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号